Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
  • 0 views
  • 15 Mar, 2022
  • 1 location
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)

This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant and the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the OncotypeDX …

renal function
platelet count
estrogen
white blood cells
palbociclib 125 mg
  • 435 views
  • 27 Feb, 2022
  • 10 locations
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients

Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most

erbb2
estrogen
progesterone
progesterone receptor
invasive breast cancer
  • 0 views
  • 08 Nov, 2020
  • 1 location
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine

ct scan
cyclophosphamide
etoposide
measurable disease
prednisone
  • 3 views
  • 23 Feb, 2022
  • 2 locations
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

This is a prospective phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.

camrelizumab
dacarbazine
lymphoma
vincristine
epirubicin
  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin

breast surgery
atezolizumab
mastectomy
taxane
programmed cell death 1 ligand 1
  • 394 views
  • 26 May, 2022
  • 414 locations
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (TCTN)

To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin

immunohistochemistry
mastectomy
estrogen
axillary lymph node dissection
taxane
  • 90 views
  • 24 Apr, 2022
  • 26 locations
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (PANSY)

This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of

immunohistochemistry
chromogenic in situ hybridization
epidermal growth factor receptor
estrogen
pertuzumab
  • 11 views
  • 20 Feb, 2022
  • 1 location
Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.

human epidermal growth factor
platelet count
estrogen
taxane
estrogen receptor
  • 4 views
  • 11 Apr, 2022
  • 76 locations
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) (GENSA)

The natural history of non-muscle-invasive bladder cancer is characterised by recurrence and progression. We compare the effectiveness of gemcitabine hydrochloride and epirubicin hydrochloride

bladder tumor
gemcitabine
transurethral resection
invasive bladder cancer
  • 0 views
  • 22 Mar, 2022
  • 1 location